Back to results

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Primary Purpose

Neovascular Age-related Macular Degeneration

Status

Terminated

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

0.5 mg Conbercept Intravitreal Injection

1.0 mg Conbercept Intravitreal Injection

2.0 mg Aflibercept Intravitreal Injection

About this trial

This is an interventional treatment trial for Neovascular Age-related Macular Degeneration

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Men and women ≥ 50 years of age at the Screening visit;
Females must be at least 1 year postmenopausal, or surgically sterilized, or, if of childbearing potential, must have a negative pregnancy test at the Screening visit;
o Women of childbearing potential must agree to use a highly effective method of contraception throughout the study.
Have received no previous treatment for neovascular AMD, including laser photocoagulation and/or photodynamic therapy (PDT) and/or IVT VEGF antagonists (treatment naïve) and;
Have active subfoveal choroidal neovascularization (CNV) lesions secondary to AMD (including polypoidal choroidal vasculopathy (PCV)) evidenced by subfoveal fluorescein angiography (FA) leakage, or definite subfoveal fluid by SD-OCT in the study eye at Screening;
Have a ETDRS BCVA letter score of 78 to 25 in the study eye at Screening;
Are willing and able to sign the study written informed consent form (ICF).

Exclusion Criteria:

Have had any prior ocular or systemic treatment (investigational or approved) or surgery for the treatment of neovascular AMD in the study eye except dietary supplements or vitamins;
Have participated as a subject in any interventional clinical trial within one month (30 days) prior to Baseline visit;
Have a subretinal hemorrhage that is either 50% or more of the total lesion area, or blood is under the fovea and is one or more disc areas in size (greater than 2.5 mm2) in the study eye at Screening;
Have any retinal pigment epithelial tears or rips in the study eye at Screening or upon examination at Baseline;
Have any vitreous hemorrhage in the study eye upon examination at Baseline or history of vitreous hemorrhage within eight weeks prior to Screening;
Have any other cause of CNV;
Have had prior pars plana vitrectomy in the study eye;
Have presence of a full thickness macular hole at Screening or upon examination at Baseline or a history of a full thickness macular hole in the study eye;
Have prior trabeculectomy or other filtration surgery in the study eye;
Have uncontrolled glaucoma;
Have active intraocular inflammation in either eye at Screening or upon examination at Baseline or a history of uveitis in either eye;
Have aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye.
Significant media opacities, including cataract, in the study eye that, in the opinion of the Investigator, could require either medical or surgical intervention during the study period;
Have any use of long acting intraocular steroids, including implants, within six months prior to Day 1, Baseline;
Have any known allergy to povidone iodine or known serious allergy to the fluorescein sodium for injection in angiography;
Any history of known contraindications indicated in the Food and Drug Administration (FDA)-approved label for the active control;
If female, be pregnant (positive urine pregnancy test at Screening) or breastfeeding.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Arm Label

0.5 mg Conbercept

1.0 mg Conbercept

Aflibercept

Arm Description

Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.

Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.

Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.

Outcomes

Primary Outcome Measures

Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eye

BCVA was assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) method

Secondary Outcome Measures

Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36

To Assess Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36

Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36

To Assess Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36

Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week

To Assess Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week

Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48

To Assess Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48

Mean change from baseline in ETDRS BCVA letter score at Week 96

To Assess Mean change from baseline in ETDRS BCVA letter score at Week 96

Number of participants with adverse events as measure of safety and tolerability

To Assess Number of participants with adverse events as measure of safety and tolerability

Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible

To Assess Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible

Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible

To Assess Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible

Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible

To Assess Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible

Full Information

NCT ID

NCT03630952

First Posted

August 11, 2018

Last Updated

June 22, 2021

Sponsor

Chengdu Kanghong Biotech Co., Ltd.

1. Study Identification

Unique Protocol Identification Number

NCT03630952

Brief Title

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Official Title

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2)

Study Type

Interventional

2. Study Status

Record Verification Date

June 2021

Overall Recruitment Status

Terminated

Why Stopped

desired primary endpoint was not met

Study Start Date

December 21, 2018 (Actual)

Primary Completion Date

September 10, 2020 (Actual)

Study Completion Date

May 19, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Chengdu Kanghong Biotech Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.

Detailed Description

A multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial, which will randomize approximately 1140 subjects in a ratio of 1:1:1 to receive IVT injections of 0.5 mg conbercept, 1.0 mg conbercept, or 2.0 mg aflibercept. The trial includes a screening period of less than or equal to 14 days, followed by a treatment period of 92 weeks (last assessment at 96 weeks) with primary efficacy analysis at 36 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Neovascular Age-related Macular Degeneration

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

1157 (Actual)

8. Arms, Groups, and Interventions

Arm Title

0.5 mg Conbercept

Arm Type

Experimental

Arm Description

Arm Title

1.0 mg Conbercept

Arm Type

Experimental

Arm Description

Arm Title

Aflibercept

Arm Type

Active Comparator

Arm Description

Intervention Type

Biological

Intervention Name(s)

0.5 mg Conbercept Intravitreal Injection

Intervention Description

Intervention Type

Biological

Intervention Name(s)

1.0 mg Conbercept Intravitreal Injection

Intervention Description

Intervention Type

Biological

Intervention Name(s)

2.0 mg Aflibercept Intravitreal Injection

Other Intervention Name(s)

Eylea®

Intervention Description

Primary Outcome Measure Information:

Title

Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eye

Description

BCVA was assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) method

Time Frame

Baseline to Week 36

Secondary Outcome Measure Information:

Title

Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36

Description

To Assess Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36

Time Frame

Baseline to Week 36

Title

Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36

Description

To Assess Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36

Time Frame

Baseline to Week 36

Title

Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week

Description

To Assess Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week

Time Frame

Baseline and Week 36

Title

Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48

Description

To Assess Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48

Time Frame

Baseline to Week 48

Title

Mean change from baseline in ETDRS BCVA letter score at Week 96

Description

To Assess Mean change from baseline in ETDRS BCVA letter score at Week 96

Time Frame

Baseline and Week 96

Title

Number of participants with adverse events as measure of safety and tolerability

Description

To Assess Number of participants with adverse events as measure of safety and tolerability

Time Frame

Baseline to Week 96

Title

Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible

Description

To Assess Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible

Time Frame

Baseline to Week 96

Title

Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible

Description

To Assess Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible

Time Frame

Baseline to Week 96

Title

Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible

Description

To Assess Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible

Time Frame

Baseline to Week 96

10. Eligibility

Sex

All

Minimum Age & Unit of Time

50 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Men and women ≥ 50 years of age at the Screening visit; Females must be at least 1 year postmenopausal, or surgically sterilized, or, if of childbearing potential, must have a negative pregnancy test at the Screening visit; o Women of childbearing potential must agree to use a highly effective method of contraception throughout the study. Have received no previous treatment for neovascular AMD, including laser photocoagulation and/or photodynamic therapy (PDT) and/or IVT VEGF antagonists (treatment naïve) and; Have active subfoveal choroidal neovascularization (CNV) lesions secondary to AMD (including polypoidal choroidal vasculopathy (PCV)) evidenced by subfoveal fluorescein angiography (FA) leakage, or definite subfoveal fluid by SD-OCT in the study eye at Screening; Have a ETDRS BCVA letter score of 78 to 25 in the study eye at Screening; Are willing and able to sign the study written informed consent form (ICF). Exclusion Criteria: Have had any prior ocular or systemic treatment (investigational or approved) or surgery for the treatment of neovascular AMD in the study eye except dietary supplements or vitamins; Have participated as a subject in any interventional clinical trial within one month (30 days) prior to Baseline visit; Have a subretinal hemorrhage that is either 50% or more of the total lesion area, or blood is under the fovea and is one or more disc areas in size (greater than 2.5 mm2) in the study eye at Screening; Have any retinal pigment epithelial tears or rips in the study eye at Screening or upon examination at Baseline; Have any vitreous hemorrhage in the study eye upon examination at Baseline or history of vitreous hemorrhage within eight weeks prior to Screening; Have any other cause of CNV; Have had prior pars plana vitrectomy in the study eye; Have presence of a full thickness macular hole at Screening or upon examination at Baseline or a history of a full thickness macular hole in the study eye; Have prior trabeculectomy or other filtration surgery in the study eye; Have uncontrolled glaucoma; Have active intraocular inflammation in either eye at Screening or upon examination at Baseline or a history of uveitis in either eye; Have aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye. Significant media opacities, including cataract, in the study eye that, in the opinion of the Investigator, could require either medical or surgical intervention during the study period; Have any use of long acting intraocular steroids, including implants, within six months prior to Day 1, Baseline; Have any known allergy to povidone iodine or known serious allergy to the fluorescein sodium for injection in angiography; Any history of known contraindications indicated in the Food and Drug Administration (FDA)-approved label for the active control; If female, be pregnant (positive urine pregnancy test at Screening) or breastfeeding.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Yan Cheng, MD, PhD

Organizational Affiliation

Chengdu Kanghong Biotechnology Co.,Ltd.

Official's Role

Study Director

Facility Information:

Facility Name

Kanghong Investigative Site

City

Phoenix

State/Province

Arizona

ZIP/Postal Code

85020

Country

United States

Facility Name

Kanghong Investigative Site

City

Phoenix

State/Province

Arizona

ZIP/Postal Code

85021

Country

United States

Facility Name

Kanghong Investigative Site

City

Springdale

State/Province

Arkansas

ZIP/Postal Code

72762

Country

United States

Facility Name

Kanghong Investigative Site

City

Arcadia

State/Province

California

ZIP/Postal Code

91006

Country

United States

Facility Name

Kanghong Investigative Site

City

Arcadia

State/Province

California

ZIP/Postal Code

91007

Country

United States

Facility Name

Kanghong Investigative Site

City

Bakersfield

State/Province

California

ZIP/Postal Code

93309

Country

United States

Facility Name

Kanghong Investigative Site

City

Encino

State/Province

California

ZIP/Postal Code

91436

Country

United States

Facility Name

Kanghong Investigative Site

City

Glendale

State/Province

California

ZIP/Postal Code

91203

Country

United States

Facility Name

Kanghong Investigative Site

City

Glendora

State/Province

California

ZIP/Postal Code

91741

Country

United States

Facility Name

Kanghong Investigative Site

City

Huntington Beach

State/Province

California

ZIP/Postal Code

92647

Country

United States

Facility Name

Kanghong Investigative Site

City

Pasadena

State/Province

California

ZIP/Postal Code

91107

Country

United States

Facility Name

Kanghong Investigative Site

City

Poway

State/Province

California

ZIP/Postal Code

92064

Country

United States

Facility Name

Kanghong Investigative Site

City

Redlands

State/Province

California

ZIP/Postal Code

92373

Country

United States

Facility Name

Kanghong Investigative Site

City

Redlands

State/Province

California

ZIP/Postal Code

92374

Country

United States

Facility Name

Kanghong Investigative Site

City

Riverside

State/Province

California

ZIP/Postal Code

92505

Country

United States

Facility Name

Kanghong Investigative Site

City

San Francisco

State/Province

California

ZIP/Postal Code

94109

Country

United States

Facility Name

Kanghong Investigative Site

City

Santa Barbara

State/Province

California

ZIP/Postal Code

93013

Country

United States

Facility Name

Kanghong Investigative Site

City

Colorado Springs

State/Province

Colorado

ZIP/Postal Code

80909

Country

United States

Facility Name

Kanghong Investigative Site

City

Waterford

State/Province

Connecticut

ZIP/Postal Code

06385

Country

United States

Facility Name

Kanghong Investigative Site

City

Boynton Beach

State/Province

Florida

ZIP/Postal Code

33426

Country

United States

Facility Name

Kanghong Investigative Site

City

Bradenton

State/Province

Florida

ZIP/Postal Code

34209

Country

United States

Facility Name

Kanghong Investigative Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33126

Country

United States

Facility Name

Kanghong Investigative Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33143

Country

United States

Facility Name

Kanghong Investigative Site

City

Stuart

State/Province

Florida

ZIP/Postal Code

34994

Country

United States

Facility Name

Kanghong Investigative Site

City

Winter Haven

State/Province

Florida

ZIP/Postal Code

33880

Country

United States

Facility Name

Kanghong Investigative Site

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30328

Country

United States

Facility Name

Kanghong Investigative Site

City

Augusta

State/Province

Georgia

ZIP/Postal Code

30909

Country

United States

Facility Name

Kanghong Investigative Site

City

Marietta

State/Province

Georgia

ZIP/Postal Code

30060

Country

United States

Facility Name

Kanghong Investigative Site

City

Elmhurst

State/Province

Illinois

ZIP/Postal Code

60126

Country

United States

Facility Name

Kanghong Investigative Site

City

Indianapolis

State/Province

Indiana

ZIP/Postal Code

46290

Country

United States

Facility Name

Kanghong Investigative Site

City

New Albany

State/Province

Indiana

ZIP/Postal Code

47150

Country

United States

Facility Name

Kanghong Investigative Site

City

Leawood

State/Province

Kansas

ZIP/Postal Code

66211

Country

United States

Facility Name

Kanghong Investigative Site

City

Springfield

State/Province

Massachusetts

ZIP/Postal Code

01107

Country

United States

Facility Name

Kanghong Investigative Site

City

Grand Rapids

State/Province

Michigan

ZIP/Postal Code

49546

Country

United States

Facility Name

Kanghong Investigative Site

City

Traverse City

State/Province

Michigan

ZIP/Postal Code

49686

Country

United States

Facility Name

Kanghong Investigative Site

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63128

Country

United States

Facility Name

Kanghong Investigative Site

City

Reno

State/Province

Nevada

ZIP/Postal Code

89502

Country

United States

Facility Name

Kanghong Investigative Site

City

Northfield

State/Province

New Jersey

ZIP/Postal Code

08205

Country

United States

Facility Name

Kanghong Investigative Site

City

Teaneck

State/Province

New Jersey

ZIP/Postal Code

07666

Country

United States

Facility Name

Kanghong Investigative Site

City

Albuquerque

State/Province

New Mexico

ZIP/Postal Code

87109

Country

United States

Facility Name

Kanghong Investigative Site

City

Brooklyn

State/Province

New York

ZIP/Postal Code

11201

Country

United States

Facility Name

Kanghong Investigative Site

City

Great Neck

State/Province

New York

ZIP/Postal Code

11021

Country

United States

Facility Name

Kanghong Investigative Site

City

Liverpool

State/Province

New York

ZIP/Postal Code

13088

Country

United States

Facility Name

Kanghong Investigative Site

City

Shirley

State/Province

New York

ZIP/Postal Code

11967

Country

United States

Facility Name

Kanghong Investigative Site

City

Asheville

State/Province

North Carolina

ZIP/Postal Code

28803

Country

United States

Facility Name

Kanghong Investigative Site

City

Winston-Salem

State/Province

North Carolina

ZIP/Postal Code

27157

Country

United States

Facility Name

Kanghong Investigative Site

City

Youngstown

State/Province

Ohio

ZIP/Postal Code

44505

Country

United States

Facility Name

Kanghong Investigative Site

City

Oklahoma City

State/Province

Oklahoma

ZIP/Postal Code

73104

Country

United States

Facility Name

Kanghong Investigative Site

City

Medford

State/Province

Oregon

ZIP/Postal Code

97504

Country

United States

Facility Name

Kanghong Investigative Site

City

Portland

State/Province

Oregon

ZIP/Postal Code

97225

Country

United States

Facility Name

Kanghong Investigative Site

City

Springfield

State/Province

Oregon

ZIP/Postal Code

97477

Country

United States

Facility Name

Kanghong Investigative Site

City

Camp Hill

State/Province

Pennsylvania

ZIP/Postal Code

17011

Country

United States

Facility Name

Kanghong Investigative Site

City

Kingston

State/Province

Pennsylvania

ZIP/Postal Code

18704

Country

United States

Facility Name

Kanghong Investigative Site

City

Ladson

State/Province

South Carolina

ZIP/Postal Code

29456

Country

United States

Facility Name

Kanghong Investigative Site

City

Rapid City

State/Province

South Dakota

ZIP/Postal Code

57701

Country

United States

Facility Name

Kanghong Investigative Site

City

Arlington

State/Province

Texas

ZIP/Postal Code

76012

Country

United States

Facility Name

Kanghong Investigative Site

City

Austin

State/Province

Texas

ZIP/Postal Code

78705

Country

United States

Facility Name

Kanghong Investigative Site

City

Austin

State/Province

Texas

ZIP/Postal Code

78731

Country

United States

Facility Name

Kanghong Investigative Site

City

Bellaire

State/Province

Texas

ZIP/Postal Code

77401

Country

United States

Facility Name

Kanghong Investigative Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75231

Country

United States

Facility Name

Kanghong Investigative Site

City

Fort Worth

State/Province

Texas

ZIP/Postal Code

76102

Country

United States

Facility Name

Kanghong Investigative Site

City

Kingwood

State/Province

Texas

ZIP/Postal Code

77339

Country

United States

Facility Name

Kanghong Investigative Site

City

McAllen

State/Province

Texas

ZIP/Postal Code

78503

Country

United States

Facility Name

Kanghong Investigative Site

City

Midland

State/Province

Texas

ZIP/Postal Code

79706

Country

United States

Facility Name

Kanghong Investigative Site

City

Temple

State/Province

Texas

ZIP/Postal Code

76502

Country

United States

Facility Name

Kanghong Investigative Site

City

Salt Lake City

State/Province

Utah

ZIP/Postal Code

84107

Country

United States

Facility Name

Kanghong Investigative Site

City

Burlington

State/Province

Vermont

ZIP/Postal Code

05401

Country

United States

Facility Name

Kanghong Investigative Site

City

Charlottesville

State/Province

Virginia

ZIP/Postal Code

22903

Country

United States

Facility Name

Kanghong Investigative Site

City

Bellevue

State/Province

Washington

ZIP/Postal Code

98004

Country

United States

Facility Name

Kanghong Investigative Site

City

Plovdiv

ZIP/Postal Code

4003

Country

Bulgaria

Facility Name

Kanghong Investigative Site

City

Sofia

ZIP/Postal Code

1408

Country

Bulgaria

Facility Name

Kanghong Investigative Site

City

Sofia

ZIP/Postal Code

1517

Country

Bulgaria

Facility Name

Kanghong Investigative Site

City

Varna

ZIP/Postal Code

9010

Country

Bulgaria

Facility Name

Kanghong Investigative Site

City

Beijing

State/Province

Beijing

ZIP/Postal Code

100044

Country

China

Facility Name

Kanghong Investigative Site

City

Shanghai

State/Province

Shanghai

ZIP/Postal Code

200031

Country

China

Facility Name

Kanghong Investigative Site

City

Shanghai

State/Province

Shanghai

ZIP/Postal Code

200080

Country

China

Facility Name

Kanghong Investigative Site

City

Tianjin

State/Province

Tianjin

ZIP/Postal Code

300384

Country

China

Facility Name

Kanghong Investigative Site

City

Brno

ZIP/Postal Code

625 00

Country

Czechia

Facility Name

Kanghong Investigative Site

City

Praha 10

ZIP/Postal Code

100 34

Country

Czechia

Facility Name

Kanghong Investigative Site

City

Praha 10

ZIP/Postal Code

10034

Country

Czechia

Facility Name

Kanghong Investigative Site

City

Praha 2

ZIP/Postal Code

128 00

Country

Czechia

Facility Name

Kanghong Investigative Site

City

Praha 5

ZIP/Postal Code

15000

Country

Czechia

Facility Name

Kanghong Investigative Site

City

Aalborg

ZIP/Postal Code

9100

Country

Denmark

Facility Name

Kanghong Investigative Site

City

Aarhus N

ZIP/Postal Code

8200

Country

Denmark

Facility Name

Kanghong Investigative Site

City

Glostrup

ZIP/Postal Code

2600

Country

Denmark

Facility Name

Kanghong Investigative Site

City

Roskilde

ZIP/Postal Code

4000

Country

Denmark

Facility Name

Kanghong Investigative Site

City

Sonderborg

ZIP/Postal Code

6400

Country

Denmark

Facility Name

Kanghong Investigative Site

City

Bordeaux

ZIP/Postal Code

33000

Country

France

Facility Name

Kanghong Investigative Site

City

Créteil

ZIP/Postal Code

94010

Country

France

Facility Name

Kanghong Investigative Site

City

Dijon

ZIP/Postal Code

21079

Country

France

Facility Name

Kanghong Investigative Site

City

Marseille

ZIP/Postal Code

13008

Country

France

Facility Name

Kanghong Investigative Site

City

Paris

ZIP/Postal Code

75010

Country

France

Facility Name

Kanghong Investigative Site

City

Paris

ZIP/Postal Code

75012

Country

France

Facility Name

Kanghong Investigative Site

City

Paris

ZIP/Postal Code

75015

Country

France

Facility Name

Kanghong Investigative Site

City

Paris

ZIP/Postal Code

75019

Country

France

Facility Name

Kanghong Investigative Site

City

Poitiers Cedex

ZIP/Postal Code

86021

Country

France

Facility Name

Kanghong Investigative Site

City

Saint-Cyr sur Loire

ZIP/Postal Code

37540

Country

France

Facility Name

Kanghong Investigative Site

City

Strasbourg

ZIP/Postal Code

67000

Country

France

Facility Name

Kanghong Investigative Site

City

Pécs

State/Province

Baranya

ZIP/Postal Code

7621

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Szeged

State/Province

Csongrád

ZIP/Postal Code

6720

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Debrecen

State/Province

Hajdu Bihar

ZIP/Postal Code

4032

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Budapest

State/Province

Pest

ZIP/Postal Code

1062

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Budapest

State/Province

Pest

ZIP/Postal Code

1076

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Budapest

State/Province

Pest

ZIP/Postal Code

1085

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Budapest

State/Province

Pest

ZIP/Postal Code

1106

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Budapest

State/Province

Pest

ZIP/Postal Code

1133

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Budapest

State/Province

Pest

ZIP/Postal Code

1204

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Zalaegerszeg

State/Province

Zala

ZIP/Postal Code

8900

Country

Hungary

Facility Name

Kanghong Investigative Site

City

Ashkelon

State/Province

Ha'Darom

ZIP/Postal Code

7830604

Country

Israel

Facility Name

Kanghong Investigative Site

City

Beer Sheva

ZIP/Postal Code

8457108

Country

Israel

Facility Name

Kanghong Investigative Site

City

Haifa

ZIP/Postal Code

31048

Country

Israel

Facility Name

Kanghong Investigative Site

City

Haifa

ZIP/Postal Code

31096

Country

Israel

Facility Name

Kanghong Investigative Site

City

Haifa

ZIP/Postal Code

3436212

Country

Israel

Facility Name

Kanghong Investigative Site

City

Jerusalem

ZIP/Postal Code

9103102

Country

Israel

Facility Name

Kanghong Investigative Site

City

Jerusalem

ZIP/Postal Code

9112001

Country

Israel

Facility Name

Kanghong Investigative Site

City

Kfar Saba

ZIP/Postal Code

4428164

Country

Israel

Facility Name

Kanghong Investigative Site

City

Petach Tikva

ZIP/Postal Code

4941492

Country

Israel

Facility Name

Kanghong Investigative Site

City

Poriyya

ZIP/Postal Code

1520800

Country

Israel

Facility Name

Kanghong Investigative Site

City

Rehovot

ZIP/Postal Code

76100

Country

Israel

Facility Name

Kanghong Investigative Site

City

Tel Aviv

ZIP/Postal Code

64239

Country

Israel

Facility Name

Kanghong Investigative Site

City

Zrifin

ZIP/Postal Code

7030000

Country

Israel

Facility Name

Kanghong Investigative Site

City

Chieti

ZIP/Postal Code

66100

Country

Italy

Facility Name

Kanghong Investigative Site

City

Firenze

ZIP/Postal Code

50134

Country

Italy

Facility Name

Kanghong Investigative Site

City

Genova

ZIP/Postal Code

16132

Country

Italy

Facility Name

Kanghong Investigative Site

City

Milano

ZIP/Postal Code

20122

Country

Italy

Facility Name

Kanghong Investigative Site

City

Milano

ZIP/Postal Code

20132

Country

Italy

Facility Name

Kanghong Investigative Site

City

Milano

ZIP/Postal Code

20157

Country

Italy

Facility Name

Kanghong Investigative Site

City

Negrar

ZIP/Postal Code

37024

Country

Italy

Facility Name

Kanghong Investigative Site

City

Roma

ZIP/Postal Code

00133

Country

Italy

Facility Name

Kanghong Investigative Site

City

Roma

ZIP/Postal Code

00198

Country

Italy

Facility Name

Kanghong Investigative Site

City

Udine

ZIP/Postal Code

33100

Country

Italy

Facility Name

Kanghong Investigative Site

City

Riga

ZIP/Postal Code

LV-1002

Country

Latvia

Facility Name

Kanghong Investigative Site

City

Riga

ZIP/Postal Code

LV-1006

Country

Latvia

Facility Name

Kanghong Investigative Site

City

Riga

ZIP/Postal Code

LV-1009

Country

Latvia

Facility Name

Kanghong Investigative Site

City

Bratislava

ZIP/Postal Code

82606

Country

Slovakia

Facility Name

Kanghong Investigative Site

City

Trenčín

ZIP/Postal Code

91171

Country

Slovakia

Facility Name

Kanghong Investigative Site

City

Zilina

ZIP/Postal Code

010 08

Country

Slovakia

Facility Name

Kanghong Investigative Site

City

Žilina

ZIP/Postal Code

01207

Country

Slovakia

Facility Name

Kanghong Investigative Site

City

Westcliff on Sea

State/Province

Essex

ZIP/Postal Code

SS0 0RY

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Southampton

State/Province

Hampshire

ZIP/Postal Code

SO16 6YD

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Gorleston-on-Sea

State/Province

Norfolk

ZIP/Postal Code

NR31 6LA

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Frimley

State/Province

Surrey

ZIP/Postal Code

GU16 7UJ

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Belfast

ZIP/Postal Code

BT12 6BA

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Bradford

ZIP/Postal Code

BD9 6RJ

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Bristol

ZIP/Postal Code

BS1 2LX

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Canterbury

ZIP/Postal Code

CT1 3NG

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Derby

ZIP/Postal Code

DE22 3NE

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Gorleston-On-Sea

ZIP/Postal Code

NR31 6LA

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Leeds

ZIP/Postal Code

LS9 7TF

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

London

ZIP/Postal Code

EC1V 2PD

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

London

ZIP/Postal Code

NW1 5QH

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

London

ZIP/Postal Code

NW10 7NS

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Sheffield

ZIP/Postal Code

S10 2JF

Country

United Kingdom

Facility Name

Kanghong Investigative Site

City

Sunderland

ZIP/Postal Code

SR2 9HP

Country

United Kingdom

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

We'll reach out to this number within 24 hrs

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Neovascular Age-related Macular Degeneration

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial